New evidence shows that patients with Long COVID syndrome continue to have higher measures of blood clotting, which may help explain their persistent symptoms, such as reduced physical fitness and fatigue.
From:
RCSI University of Medicine and Health Sciences
August
16, 2021 -- The study, led by researchers from RCSI University of Medicine and
Health Sciences, is published in the Journal of Thrombosis and
Haemostasis.
Previous work by the same group studied
the dangerous clotting observed in patients with severe acute COVID-19.
However, far less is known about Long COVID syndrome, where symptoms can last
weeks to months after the initial infection has resolved and is estimated to
affect millions of people worldwide.
The researchers examined 50 patients
with symptoms of Long COVID syndrome to better understand if abnormal blood
clotting is involved.
They discovered that clotting markers
were significantly elevated in the blood of patients with Long COVID syndrome
compared with healthy controls. These clotting markers were higher in patients
who required hospitalisation with their initial COVID-19 infection, but they
also found that even those who were able to manage their illness at home still
had persistently high clotting markers.
The researchers observed that higher
clotting was directly related to other symptoms of Long COVID syndrome, such as
reduced physical fitness and fatigue. Even though markers of inflammation had
all returned to normal levels, this increased clotting potential was still
present in Long COVID patients.
"Because clotting markers were
elevated while inflammation markers had returned to normal, our results suggest
that the clotting system may be involved in the root cause of Long COVID
syndrome," said Dr Helen Fogarty, the study's lead author, ICAT Fellow and
PhD student at the Irish Centre for Vascular Biology in the RCSI School of
Pharmacy and Biomolecular Sciences.
This work was funded by the Welcome
Trust, the Health Research Board (HRB) Irish Clinical Academic Training (ICAT)
programme as well as the HRB-funded Irish COVID-19 Vasculopathy Study (ICVS).
The work was also supported by a philanthropic grant from the 3M Foundation to
RCSI University of Medicine and Health Sciences in support of COVID-19
research.
"Understanding the root cause of a
disease is the first step toward developing effective treatments," said
Professor James O'Donnell, Director of the Irish Centre for Vascular Biology,
RCSI and Consultant Haematologist in the National Coagulation Centre in St
James's Hospital, Dublin.
"Millions of people are already
dealing with the symptoms of Long COVID syndrome, and more people will develop
Long COVID as the infections among the unvaccinated continue to occur. It is
imperative that we continue to study this condition and develop effective
treatments."
https://www.sciencedaily.com/releases/2021/08/210816125717.htm
No comments:
Post a Comment